Links between toll-like receptor 4 and breast cancer

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Ahmed, Abubakr ^a   Redmond, H Paul ^a   Wang, Jiang Huai ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

Breast cancer; Signal transduction pathways; TLR4; Tumor progression and metastasis

Indexed keywords

INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6;

ADAPTIVE IMMUNITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER LOCALIZATION; CANCER SUSCEPTIBILITY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE ASSOCIATION; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84885762423     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22945     Document Type: Review

References (80)

1. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12:895-904; http://dx.doi.org/10.1038/nm1469.
2. Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007; 57:93-107; http://dx.doi.org/10.1111/j.1600-0897.2006.00441.x.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; http://dx.doi.org/10.1038/nature01322.
4. Beachy PA, Karhadkar SS, Berman DM. Mending and malignancy. Nature 2004; 431:402; http://dx.doi.org/10.1038/431402a.
5. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 1999; 81:1311-7; http://dx.doi.org/10.1038/sj.bjc.6694369.
6. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002; 101:415-22; http://dx.doi.org/10.1002/ijc.10632.
7. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991; 3-11.
8. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563:1-17; http://dx.doi.org/10.1016/j.ejphar.2007.02.018.
9. Okamoto H, Shoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967; 11:323-6; PMID:4875331.
10. Kikkawa F, Kawai M, Oguchi H, Kojima M, Ishikawa H, Iwata M, et al. Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur J Cancer 1993; 29:1542-6; http://dx.doi.org/10.1016/0959-8049(93)90291-M.
11. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 1994; 168:36-40; http://dx.doi.org/10.1016/S0002-9610(05)80068-6.
12. Razack AHA. Bacillus Calmette-Guerin and bladder cancer. Asian J Surg 2007; 30:302-9; http://dx.doi.org/10.1016/S1015-9584(08)60045-7.
13. Uehori J, Fukase K, Akazawa T, Uematsu S, Akira S, Funami K, et al. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol 2005; 174:7096-103.
14. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 2009; 46:2876-84; http://dx.doi.org/10.1016/j.molimm.2009.06.016.
15. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317:124-7; http://dx.doi.org/10.1126/science.1140488.
16. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-4;http://dx.doi.org/10.1126/science.1140485.
17. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66:3859-68; http://dx.doi.org/10.1158/0008-5472.CAN-05-3948.
18. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002; 101:415-22; http://dx.doi.org/10.1002/ijc.10632.
19. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004; 6:297-305; http://dx.doi.org/10.1016/j.ccr.2004.08.012.
20. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86:973-83; http://dx.doi.org/10.1016/S0092-8674(00)80172-5.
21. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7; http://dx.doi. org/10.1038/41131.
22. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8; http://dx.doi.org/10.1126/science.282.5396.2085.
23. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169:10-4.
24. Takeuchi O, Kawai T, Mühlradt PF, Morr M, Radolf JD, Zychlinsky A, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13:933-40; http://dx.doi. org/10.1093/intimm/13.7.933.
25. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8; http://dx.doi. org/10.1038/35099560.
26. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-103; http://dx.doi.org/10.1038/35074106.
27. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-9; http://dx.doi.org/10.1126/science.1093620.
28. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3:499; http://dx.doi.org/10.1038/ni0602-499.
29. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598-603; http://dx.doi.org/10.1073/pnas.0400937101.
30. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263-70; http://dx.doi. org/10.1038/nm1191.
31. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5; http://dx.doi.org/10.1038/35047123.
32. Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005; 201:19-25; http://dx.doi.org/10.1084/jem.20041836.
33. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303:1522-6; http://dx.doi. org/10.1126/science.1094351.
34. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195:99-111; http://dx.doi. org/10.1084/jem.20001858.
35. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279:7370-7; http://dx.doi.org/10.1074/jbc.M306793200.
36. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002; 168:5989-92.
37. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229-33; http://dx.doi. org/10.1074/jbc.M100099200.
38. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptormediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168:5233-9.
39. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, et al. The matrix component biglycan is proinflammatory and signals through Tolllike receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223-33; http://dx.doi. org/10.1172/JCI23755.
40. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167:2887-94.
41. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11:1173-9; http://dx.doi.org/10.1038/nm1315.
42. Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-Nejad P, et al. The endoplasmic reticulumresident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002; 277:20847-53; http://dx.doi. org/10.1074/jbc.M200425200.
43. Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 2006; 176:7021-7.
44. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005; 52:2936-46; http://dx.doi. org/10.1002/art.21238.
45. West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren HG, et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 2004; 305:1153-7; http://dx.doi.org/10.1126/science.1099153.
46. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95; http://dx.doi.org/10.1038/ni1112.
47. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9:57-63; http://dx.doi.org/10.1038/nrc2541.
48. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76; http://dx.doi.org/10.1146/annurev.immunol. 21.120601.141126.
49. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007; 76:447-80; http://dx.doi.org/10.1146/annurev.biochem.76.060605.122847.
50. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42:145-51; http://dx.doi.org/10.1016/j.cyto.2008.01.006.
51. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-Nature 2002; 416:750-6; http://dx.doi.org/10.1038/nature736.
52. Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007; 204:2407-22; http://dx.doi.org/10.1084/jem.20070628.
53. Kim TW, Staschke K, Bulek K, Yao J, Peters K, Oh KH, et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med 2007; 204:1025-36; http://dx.doi.org/10.1084/jem.20061825.
54. Lye E, Dhanji S, Calzascia T, Elford AR, Ohashi PS. IRAK-4 kinase activity is required for IRAK-4-dependent innate and adaptive immune responses. Eur J Immunol 2008; 38:870-6; http://dx.doi.org/10.1002/eji.200737429.
55. Lye E, Mirtsos C, Suzuki N, Suzuki S, Yeh WC. The role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling. J Biol Chem 2004; 279:40653-8; http://dx.doi.org/10.1074/jbc.M402666200.
56. Swantek JL, Tsen MF, Cobb MH, Thomas JA. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J Immunol 2000; 164:4301-6.
57. Keating SE, Maloney GM, Moran EM, Bowie AG. IRAK-2 participates in multiple toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J Biol Chem 2007; 282:33435-43; http://dx.doi.org/10.1074/jbc.M705266200.
58. Gohda J, Matsumura T, Inoue J. Cutting edge: TNFRassociated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domaincontaining adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling. J Immunol 2004; 173:2913-7.
59. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005; 6:1087-95; http://dx.doi.org/10.1038/ni1255.
60. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410:37-40; http://dx.doi.org/10.1038/35065000.
61. Lu YC, Kim I, Lye E, Shen F, Suzuki N, Suzuki S, et al. Differential role for c-Rel and C/EBPbeta/δ in TLRmediated induction of proinflammatory cytokines. J Immunol 2009; 182:7212-21; http://dx.doi.org/10.4049/jimmunol.0802971.
62. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301:640-3; http://dx.doi.org/10.1126/science.1087262.
63. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M, et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004; 5:503-7; http://dx.doi.org/10.1038/ni1061.
64. Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-kappaB activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem 2005; 280:36560-6; http://dx.doi.org/10.1074/jbc.M506831200.
65. Guo B, Cheng G. Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK. J Biol Chem 2007; 282:11817-26; http://dx.doi.org/10.1074/jbc.M700017200.
66. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003; 4:491-6; http://dx.doi.org/10.1038/ni921.
67. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005; 26:469-76; http://dx.doi.org/10.1016/j.it.2005.06.009.
68. Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res 2005; 15:407-22; http://dx.doi.org/10.1038/sj.cr.7290309.
69. Hironaka K, Yamaguchi Y, Okita R, Okawaki M, Nagamine I. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Anticancer Res 2006; 26(5B):3701-7.
70. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, et al. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 1996; 32:1712-8; http://dx.doi.org/10.1016/0959-8049(96)00186-4.
71. Chicoine MR, Zahner M, Won EK, Kalra RR, Kitamura T, Perry A, et al. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 2007; 60:372-81; http://dx.doi.org/10.1227/01.NEU.0000249280.61761.2E.
72. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65:5009-14; http://dx.doi.org/10.1158/0008-5472.CAN-05-0784.
73. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69:3105-13; http://dx.doi.org/10.1158/0008-5472.CAN-08-3838.
74. Yusuf N, Nasti TH, Long JA, Naseemuddin M, Lucas AP, Xu H, et al. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 2008; 68:615-22; http://dx.doi.org/10.1158/0008-5472.CAN-07-5219.
75. Liao SJ, Zhou YH, Yuan Y, Li D, Wu FH, Wang Q, et al. Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration. Breast Cancer Res Treat 2012; 133:853-63; http://dx.doi.org/10.1007/s10549-011-1844-0.
76. González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010; 10:665; http://dx.doi.org/10.1186/1471-2407-10-665.
77. Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010; 29:92; http://dx.doi.org/10.1186/1756-9966-29-92.
78. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68:4026-30; http://dx.doi.org/10.1158/0008-5472.CAN-08-0427.
79. Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, et al. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast 2012; 21:534-8; http://dx.doi.org/10.1016/j.breast.2012.04.001.
80. Ahmed A, Wang JH, Redmond HP. Silencing of TLR4 Increases Tumor Progression and Lung Metastasis in a Murine Model of Breast Cancer. Ann Surg Oncol 2012; 1:1-8.